Holicek, Peter http://orcid.org/0000-0002-0268-4915
Truxova, Iva
Rakova, Jana
Salek, Cyril
Hensler, Michal
Kovar, Marek
Reinis, Milan
Mikyskova, Romana
Pasulka, Josef
Vosahlikova, Sarka
Remesova, Hana
Valentova, Iva
Lysak, Daniel
Holubova, Monika
Kaspar, Petr
Prochazka, Jan
Kasikova, Lenka
Spisek, Radek
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Fucikova, Jitka http://orcid.org/0000-0002-8423-479X
Article History
Received: 17 November 2022
Revised: 28 February 2023
Accepted: 9 March 2023
First Online: 24 March 2023
Competing interests
: LG is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. All other authors have no conflicts to declare.